Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment

Journal of Periodontology

Volumn 80, Issue 8, 2009, Pages 1274-1280

  Buduneli, Nurcan ^a   Buduneli, Eralp ^a   Kütükçüler, Necil ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Chronic periodontitis; Gingival crevicular fluid; Interleukin 17; Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand; Smoking

Indexed keywords

INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; CHEMISTRY; CHRONIC PERIODONTITIS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GINGIVA BLEEDING; GINGIVITIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOTIVATION; MOUTH HYGIENE; PATIENT EDUCATION; PERIODONTICS; PREVENTIVE DENTISTRY; SMOKING; TOOTH PLAQUE;

ADULT; CHRONIC PERIODONTITIS; DENTAL PLAQUE; DENTAL PLAQUE INDEX; DENTAL SCALING; FEMALE; FOLLOW-UP STUDIES; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; MOTIVATION; ORAL HYGIENE; OSTEOPROTEGERIN; PATIENT EDUCATION AS TOPIC; PERIODONTAL INDEX; RANK LIGAND; ROOT PLANING; SMOKING;

EID: 68749118264     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2009.090106     Document Type: Article

References (44)

1. Haber J., Wattles J., Crowley M., Mandell R., Joshipura K., Kent R. L. Evidence for cigarette smoking as a major risk factor for periodontitis. J Periodontol 1993;64:16-23.
2. Calsina G., Ramon J. M., Echeverria J. J. Effects of smoking on periodontal tissues. J Clin Periodontol 2002;29:771-776.
3. Ah M. K., Johnson G. K., Kaldahl W. B., Patil K. D., Kalkwarf K. L. The effect of smoking on the response to periodontal therapy. J Clin Periodontol 1994;21:91-97.
4. Boström L., Linder L. E., Bergström J. Influence of smoking on the outcome of periodontal surgery. A 5-year follow-up. J Clin Periodontol 1998;25:194-201.
5. Renvert S., Dahlen G., Wikström M. The clinical and microbiological effects of non-surgical periodontal therapy in smokers and non-smokers. J Clin Periodontol 1998;25:153-157.
6. Preber H., Bergström J., Linder L. E. Occurrence of periopathogens in smoker and non-smoker patients. J Clin Periodontol 1992;19:667-671.
7. Buduneli N., Baylas H., Buduneli E., Türkoǧlu O., Dahlen G. Evaluation of the relationship between smoking during pregnancy and subgingival microbiota. J Clin Periodontol 2005;32:68-74.
8. Tappia P. S., Troughton K. L., Langley-Evans S. C., Grimble R. F. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 1995;88:485-489.
9. Boström L., Linder L. E., Bergström J. Smoking and crevicular fluid levels of IL-6 and TNF-α in periodontal disease. J Clin Periodontol 1999;26:352-357.
10. Rawlinson A., Grummitt J. M., Walsh T. F., Douglas C. W. I. Interleukin 1 and receptor antagonist levels in gingival crevicular fluid in heavy smokers versus non-smokers. J Clin Periodontol 2003;30:42-48.
11. Buduneli N., Buduneli E., Kardesxler L., Lappin D., Kinane D. F. Plasminogen activator system in smokers and non-smokers with and without periodontal disease. J Clin Periodontol 2005;32:417-424.
12. Buduneli N., Kardesxler L., Işik H., et al. Effects of smoking and gingival inflammation on salivary antioxidant capacity. J Clin Periodontol 2006;33:159-164.
13. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M. T., Martin T. J. Modulation of osteoclast differentiation and function by the new members of the tumour necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357. (Pubitemid 30649812)
14. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
15. Quinn J. M. W., Horwood N. J., Elliott J., Gillespie M. T., Martin T. J. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-1466.
16. Horwood N. J., Kartsogiannis V., Quinn J. M. W., Romas E., Martin T. J., Gillespie M. T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-150.
17. Lacey D. L., Timms E., Tan H.-L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
18. Kong Y. Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
19. Mogi M., Otogoto J., Ota N., Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
20. Vernal R., Chaparro A., Graumann R., Puente J., Valenzuela M. A., Gamonal J. Levels of cytokine receptor activator of nuclear factor κB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-1591.
21. Lu H.-K., Chen Y.-L., Chang H.-C., Li C.-L., Kuo M. Y-P. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006;41:354-360.
22. Bostanci N., İlgenli T., Emingil G., et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
23. Arikan F., Buduneli N., Kütükçüler N. Osteoprotegerin levels in peri-implant crevicular fluid. Clin Oral Implants Res 2008;19:283-288.
24. Buduneli N., Biyikoǧlu B., Sherrabeh S., Lappin D. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients. J Clin Periodontol 2008;35:846-852.
25. Kramer J. M., Gaffen S. L. Interleukin-17: A new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 2007;78:1083-1093.
26. Lubberts E., van Den Bersselaar L., Oppers-Walgreen B., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-2662.
27. Yu J. J., Ruddy M. J., Wong G. C., et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 2007;109:3794-3802.
28. Takahashi K., Azuma T., Motohira H., Kinane D. F., Kitetsu S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol 2005;32:369-374.
29. Vernal R., Dutzan N., Chaparro A., Puente J., Valenzuela M. A., Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005;32:383-389.
30. Page R. C., Eke P. I. Case definitions for use in population-based surveillance of periodontitis. J Periodontol 2007;78:1387-1399.
31. Badersten A., Nilveus R., Egelberg J. Effect of nonsurgical periodontal therapy. (IV) Operator variability. J Clin Periodontol 1985;12:190-200.
32. Silness J., Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
33. Löe H., Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533-551.
34. Saxer U. P., Mühlemann H. R. Motivation and instruction (in German). Schweiz Mschr Zahnkeilk 1975;85:905-919.
35. Hsu H., Lacey D. L., Dunstan C. R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545.
36. Simonet W. S., Lacey D. L., Dunstan C. R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
37. Kim S. M., Lee J., Ryu O. H., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 2005;63:594-598.
38. Nagasawa T., Kobayashi H., Kiji M., et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002;130:338-344.
39. Grossi S. G., Zambon J. J., Ho A. W., et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol 1994;65:260-267.
40. Grossi S. G., Genco R. J., Machtei E. E., Ho A. W., Koch G., Dunford R. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. J Periodontol 1995;66:23-29.
41. 2 production by osteoblasts. Life Sci 2006;78:1733-1740.
42. Lappin D. F., Sherrabeh S., Jenkins W. M., Macpherson L. M. Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive-therapy periodontitis patients. J Clin Periodontol 2007;34:271-277.
43. Crotti T., Smith M. D., Hirsch R., et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-387.
44. Johnson R. B., Wood N., Serio F. G. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004;75:37-43.